KraneShares MSCI All China Hlth Care ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
KraneShares MSCI All China Health Care Index ETF KURE
Morningstar’s Analysis KURE
Will KURE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
BeOne Medicines Ltd Ordinary Shares | 8.83 | 10M | Healthcare |
Innovent Biologics Inc | 8.56 | 10M | Healthcare |
WuXi Biologics (Cayman) Inc | 8.06 | 9M | Healthcare |
Wuxi AppTec Co Ltd Class A | 5.79 | 7M | Healthcare |
Akeso Inc Ordinary Shares | 4.68 | 5M | Healthcare |
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 4.45 | 5M | Healthcare |
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 4.36 | 5M | Healthcare |
CSPC Pharmaceutical Group Ltd | 3.78 | 4M | Healthcare |
Sino Biopharmaceutical Ltd | 3.74 | 4M | Healthcare |
Genscript Biotech Corp Class H | 3.61 | 4M | Healthcare |